Zevra Therapeutics, Inc. · NASDAQ:ZVRA
Zevra Therapeutics — Merger or Acquisition (August 2023)
15 slides from Zevra Therapeutics's merger presentation, Aug 31, 2023
Slide 1: Zevra Investor Call: Acer Acquisition
Zevra Investor Call: Acer Acquisition August 31, 2023 Exhibit 99.2
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, includ
Slide 3: Important Additional Information Regarding Transactions to be Filed with the SEC
Important Additional Information Regarding Transactions to be Filed with the SEC In connection with the proposed transaction(s), Zevra Therapeutics, Inc. (Zevra) and Acer Therapeutics, Inc. (Acer) will file relevant materials with the SEC, including a Zevra registration statement on Form S-4 that wi
Slide 4: OLPRUVA Important Safety Information
OLPRUVATM Important Safety Information OLPRUVA [ol proo vah] (sodium phenylbutyrate) for oral suspension This summary does not include all information about OLPRUVA and is not meant to take the place of discussions with your healthcare provider about your or your child’s treatment. Please read this
Slide 5: OLPRUVA Important Safety Information (continued)
OLPRUVATM Important Safety Information (continued) How should I or my child take OLPRUVA? Read the detailed Instructions for Use that comes with OLPRUVA for information about the right way to prepare and take a dose of OLPRUVA. Take OLPRUVA exactly as prescribed by your healthcare provider. Your hea
Slide 6: Executing on Zevra's Strategy to Become a Leading Rare Disease Therapeutics Company
Executing on Zevra’s Strategy to Become a Leading Rare Disease Therapeutics Company Adding a complementary rare disease portfolio, accelerating revenue potential and cost synergies Zevra to acquire Acer Therapeutics in a stock exchange transaction for $0.61 per share, or $15M of Zevra’s common stock
Slide 7: Acer Acquisition Accelerates Zevra's Growth into Commercial Organization and Expands Development Pipeline
PHASE 1 PHASE 2 PHASE 3 NDA FDA Approved Next Milestone NDA Resubmission Q4 2023 Interim P2 Analysis Q3 2023 Trial ongoing On track to receive next sales milestone Approved and commercially available in US Phase 3 trial ongoing Highly complementary portfolio targeting rare diseases Upcoming mileston
Slide 8: Urea Cycle Disorders (UCDs)
Urea Cycle Disorders (UCDs) UCDs are a group of rare, genetic disorders caused by mutations that result in a deficiency of one of the six enzymes or two transporters of the urea cycle, including carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase
Slide 9: UCDs: An area of high unmet need
UCDs: An area of high unmet need Currently, phenylbutyrate is standard of care for patients with UCDs Palatability, odor, preparation, route of administration and packaging are the most important attributes for treatment adherence among patients with UCDs1 Adherence can also be affected when patient
Slide 10: OLPRUVA is a Novel Formulation of Phenylbutyrate with Convenient, Single-Dose Packaging
OLPRUVATM is a Novel Formulation of Phenylbutyrate with Convenient, Single-Dose Packaging Phenylbutyrate Formulations OLPRUVA Raviciti® Buphenyl® Pheburane® Efficacy and Safety in UCDs Formulation Dual-coated oral pellets Clear, oily liquid Powder or Tablets Single-coated oral pellets Palatability T
Slide 11: OLPRUVA Designed to Address Patient Pain Points
OLPRUVATM Designed to Address Patient Pain Points Palatable Convenient individual dose packets support dosing accuracy Pre-Measured Dual-coating formulation designed for palatability Portable Discrete single-dose envelopes are easily carried when on the go
Slide 12: Vascular Ehlers-Danlos Syndrome (vEDS)
Vascular Ehlers-Danlos Syndrome (vEDS) Acer’s pipeline includes EDSIVOTM (celiprolol) an investigational treatment for vEDS in patients with a confirmed type III collagen (COL3A1) mutation Inherited, genetic disorder caused by mutations in the genes responsible for the structure, production, or proc
Slide 13: Complementary portfolios have the potential to provide scale and efficiency
Complementary portfolios have the potential to provide scale and efficiency Zevra + Acer = Expected Synergies Prescribing Physicians/ Specialty Pharmacies Patient Services Across Indications Data Management Systems Workforce & Functional Capabilities Existing Commercial Contracts and Sales Organizat
Slide 14: Capital Efficient Transaction Structure
Capital Efficient Transaction Structure Series of transactions designed to add value, mitigate risk and capture opportunities Debt Purchase Purchased Acer’s secured debt of $35.3M from Nantahala Capital Paid $28.5M in consideration as follows: $12M in cash from Zevra’s existing margin loan facility
Slide 15: Zevra Positioned for Success in Rare Disease
Zevra Positioned for Success in Rare Disease Continued Strategic Focus on Rare Disease Focus on delivering therapies addressing significant unmet needs in rare disease Leveraging unique insights and capabilities to develop rare disease therapies Strong relationships with rare disease community – inc
Zevra Therapeutics — Merger or Acquisition (August 2023) on 6ix